Zydus Cadila Vaccine Approval : Zydus Cadila Vaccine News

ZyCoV-D is a Plasmid DNA vaccine which when administered produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

Facts about ZyCoV-D

• ZyCoV-D is an intradermal vaccine, which will be administered in three doses.

• It will be applied using The PharmaJet® needle free system, Tropis®, which can also lead to a significant reduction in any kind of side effects.

• ZyCoV-D is stored at 2-8 degree C but has shown good stability at temperatures of 25 degree C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and reduce any cold chain breakdown challenges leading to vaccine wastage.

• The plasmid DNA platform provides ease of manufacturing with minimal biosafety requirements (BSL-1).

• Also being a Plasmid DNA vaccine, ZyCoV-D doesn’t have any problem associated with vector based immunity.

• The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus, such as those already occurring.

• The results of the Phase I part of the Phase I/II clinical trial have already been published in the EClinical Medicine Journal of Lancet.

Zydus’ Vaccine research programme

Vaccine Technology Centre of Zydus Cadila has wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate and other subunit vaccines for unmet needs. In fact, Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu during the pandemic in 2010.

In past, it has also indigenously developed numerous vaccines successfully including tetravalent seasonal influenza vaccine (first company in India to indigenously develop and commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine (first Indian company to indigenously develop and receive market authorization), Measles containing vaccines (MR, MMR, Measles), Typhoid conjugate vaccine, pentavalent vaccine (DPT-HepB-Hib) etc to name a few. The company also has a strong pipeline of vaccines like Measles-Mumps-Rubella-Varicella (MMRV), Human papillomavirus vaccine, Hepatitis A, Hepatitis E vaccines which are at various stages of development

About Zydus Cadila Zydus

Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines. The group employs 25,000 people worldwide and is dedicated to creating healthier communities globally. For more information, please visit www.zyduscadila.com.